Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022
August 08 2022 - 8:50AM
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:
TCRT), today announced that it will report financial results for
the second quarter ended June 30, 2022 on Monday, August 15, 2022,
before the open of U.S. markets. Following the announcement, the
Company will host a conference call and webcast at 8:30 a.m. ET to
provide a corporate update and review the financial results.
Register for the live webcast using the link
here or by visiting the “Investors” section of the Alaunos website
at www.alaunos.com. To participate via telephone, please register
in advance at this link. Upon registration, all telephone
participants will receive a confirmation email detailing how to
join the conference call, including the dial-in number along with a
unique passcode and registrant ID that can be used to access the
call. After the live webcast, the event will be archived on the
Company’s website for approximately 30 days after the call.
About Alaunos
TherapeuticsAlaunos is a clinical-stage oncology-focused
cell therapy company, focused on developing T-cell receptor (TCR)
therapies based on its proprietary, non-viral Sleeping Beauty gene
transfer technology and its TCR library targeting shared
tumor-specific hotspot mutations in key oncogenic genes including
KRAS, TP53 and EGFR. The Company has clinical and strategic
collaborations with The University of Texas MD Anderson Cancer
Center and the National Cancer Institute. For more information,
please visit www.alaunos.com.
Investor Relations Contact:Alex
LoboStern Investor RelationsAlex.lobo@sternir.com
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Apr 2023 to Apr 2024